

**National Cancer Institute  
Institutional Review Board  
AGENDA  
FEBRUARY 10, 2014  
1:00 – 5:00 pm  
CRC/3-1608**

- 1. Review of Draft Minutes, January 27, 2014**
- 2. Announcements**
- 3. Old Business**
- 4. New Business**
- 5. Problem Report Forms**
- 6. Other Expedited Actions**
- 7. Continuing Reviews**
- 8. Amendment**     11C0073K, "A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation from Related or Matched Unrelated Donors in Pediatric Patients with Solid Tumors and Leukemias" - Nirali Shah, PI
- 9. Amendment**     13C0063D, "A Phase I, Open-label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C, a Monoclonal anti-PD-L1 antibody, in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications" - James Gulley, PI
- 10. Amendment**     13C0214C, "Phase II Study of Metastatic Cancer that Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes" - Steve Rosenberg, PI
- 11. Initial Review**   P131486, "An Exploratory Study of Voicing My CHOICES as a Tool for Advanced Care Planning in Young Adults with Metastatic, Recurrent, or Progressive Cancer" - Lori Wiener, PI